A Structurally Stabilized Lipopolymer Nanoplatform Targeting Pan-Tissue Antigen-Presenting Cells Enables Durable in situ mRNA Cancer Immunotherapy
{{output}}
Messenger RNA (mRNA) vaccines have transformed cancer immunotherapy, yet delayed immune activation, multi-dose requirements, and poor efficacy in immunosuppressive tumor microenvironments (TMEs) hinder current platforms. Here, a structurally stabilized lipopol... ...
